Menu
Not yet recruiting NCT06849102

NeuroReAlign Therapy for Balance and Gait Rehabilitation in Stroke Survivors

No phase Interventional Stroke

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: NeuroReAlign Therapy, conventional physiotherapy interventions.
Who it may be relevant to
Registry conditions: Stroke. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Effects of NeuroReAlign Therapy on Balance and Gait in Stroke Survivors: a Randomized Controlled Trial

Overview

The goal of this randomized controlled trial is to investigate the effects of NeuroReAlign Therapy on balance and gait in stroke survivors in the chronic stage (\>6 months). The study will include male and female participants aged 18-70 years. The main questions it aims to answer are: Does NeuroReAlign Therapy improve balance in stroke survivors compared to conventional physiotherapy? Does NeuroReAlign Therapy enhance gait performance more effectively than conventional physiotherapy? Researchers will compare NeuroReAlign Therapy to conventional physiotherapy to determine its effects on balance and gait. Participants will: Undergo NeuroReAlign Therapy or conventional physiotherapy for 4 weeks. Have their balance assessed using the Berg Balance Scale (BBS), Activities-Specific Balance Confidence Scale (ABC Scale), and Fear of Falling Questionnaire (FoFQ). Have their gait evaluated using the Dynamic Gait Index (DGI), Rivermead Mobility Index (RMI), Timed Up and Go (TUG), 6-Minute Walk Test (6MWT), and 10-Meter Walk Test (10MWT). Complete outcome assessments at baseline and after the intervention (week 4).

Interventions

  • Other NeuroReAlign Therapy
    Patients in this group will receive NeuroReAlign Therapy, including motor training (e.g., treadmill training, balance training), multimodal sensory stimulation (e.g., proprioceptive and visual), cognitive training (e.g., traditional cognitive exercise), and motivation, for 45 minutes per session, 3 times weekly, for 4 weeks.
  • Other conventional physiotherapy interventions
    Patients in this group will receive conventional physiotherapy interventions, including treadmill training, balance training, strengthening and stretching lower limb muscles, for 45 minutes per session, 3 times weekly, for 4 weeks.

Primary outcome measures

  • Dynamic Gait Index (DGI) [Time frame: At baseline (week 0) and after the intervention (week 4)]
Secondary outcome measures (7)
  • Berg Balance Scale (BBS) [Time frame: At baseline (week 0) and post-intervention (week 4)]
  • Activities-Specific Balance Confidence Scale (ABC Scale) [Time frame: At baseline (week 0) and post-intervention (week 4)]
  • Fear of Falling Questionnaire (FoFQ) [Time frame: At baseline (week 0) and post-intervention (week 4)]
  • Rivermead Mobility Index (RMI) [Time frame: At baseline (week 0) and post-intervention (week 4)]
  • Timed Up and Go (TUG) [Time frame: At baseline (week 0) and post-intervention (week 4)]
  • 10-Meter Walk Test (10MWT) [Time frame: At baseline (week 0) and post-intervention (week 4)]
  • 6-Minute Walk Test (6MWT) [Time frame: At baseline (week 0) and post-intervention (week 4)]

Eligibility criteria

Inclusion criteria

  • Patients with ischemic or hemorrhagic stroke
  • Have a stroke more than 6 months
  • Age between 18 and 70

Exclusion criteria

  • Patients with severe cognitive impairments
  • Patients cannot walk independently

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06849102 · ADA/1099

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗